In particular, Ricciardi et al. demonstrated in vitro the anti-leukemic activity of the novel CPT1A reversible inhibitor ST1326 on leukemia cell lines and primary cells obtained from patients with hematologic malignancies, which induces cell growth arrest, mitochondrial damage, and apoptosis32. The gene discussed is CPT1A; the disease is leukemia.